Foresight Diagnostics (a Natera company)

Foresight Diagnostics, now a part of Natera, is a precision medicine company committed to enhancing cancer patient care through advanced detection methodologies. Founded in 2020 by four Stanford University visionaries—physicians and scientists—the company is noted for its high-performing circulating tumor DNA (ctDNA) assays. By pioneering the phased variant detection method, its flagship product, Foresight CLARITY™, significantly increases the accuracy of ctDNA tests and minimal residual disease measurements.

Acquired by Natera for $275 million in December 2025, Foresight Diagnostics operates a state-of-the-art CLIA laboratory in Boulder, Colorado. The company's focus spans Biotechnology, Health Care, and Pharmaceutical sectors, aiming to redefine cancer diagnostics. This strategic acquisition underscores Natera's commitment to advancing precision oncology solutions in the United States.